ZVRA Zevra Therapeutics, Inc.

NASDAQ
$11.32

Zevra Therapeutics, Inc. (ZVRA) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal In line Selling ran in line with ZVRA's own trailing one-year pace, with 77% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 2 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
2
2 transactions
Purchases
$0
0 shares
Sales
$613.2K
54,966 shares
Net activity
-$613.2K
purchases less sales

How much of that selling was preplanned? 77% planned / 23% discretionary

10b5-1 plan sales $474.8K 1 transaction · 42,666 shares
Discretionary sales $138.4K 1 transaction · 12,300 shares

Largest single sale: $474.8K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: September 12, 2025 — 1.0 years ago, by FAVORITO TAMARA A .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Thompson Rahsaan Chief Legal & Compliance Sell 10b5-1 42,666 $11.13 $474.8K 37,569 −53.2% of holding
Watton Corey Michael Director Sell 12,300 $11.25 $138.4K 1,800 −87.2% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.